A Phase 1/2 interventional study of Paracetamol 3% and Placebo injection containing Saline solution 0.9% in Phase 1: Pain Management and Phase 2: Pain Management, sponsored by Sintetica SA. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-27.
Sponsored by Sintetica SA · Phase 1/2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 86th largest by enrollment, is one of 9 that started in 2016, is one of 2 in phase 1/2, and was the 86th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is close to the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Sintetica SA has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Two-part study of intrathecal paracetamol administered immediately before spinal anaesthesia in patients scheduled for hip replacement surgery
This is a prospective, single centre, two-part, three doses study. Part 1 is a Phase I, three cohorts, dose-ascending, open-label, safety study. Part 2 is a Phase II, randomised, parallel-group, double-blind, placebo-controlled, exploratory efficacy and safety study The objective of the study is to investigate the efficacy and safety of a single intrathecal injection of paracetamol, administered at 3 doses to 3 active treatment groups, as compared to placebo solution, for post-operative analgesia of hip replacement surgery performed under spinal anaesthesia. Patients scheduled for hip replacement surgery will be randomised into 4 treatment groups (15 patients per group) to receive either one of the 3 single doses of paracetamol 3% (D1: 60 mg, D2: 90 mg, D3: 120 mg) or placebo solution (P: saline solution) by intrathecal (IT) injection. Immediately after paracetamol or placebo IT administration, all patients will receive a single IT dose of Hyperbaric Bupivacaine HCl 0.5% (12.5 mg for ≤ 160 cm-tall patients and 15 mg for > 160 cm-tall patients). The time interval between paracetamol IT and bupivacaine IT administrations should not exceed 2 min.
The study will include a screening phase (Visit 1, Days -21/1), a treatment phase (paracetamol IT administration, anaesthesia and surgical procedure: Visit 2, Day 1) and a follow-up phase including an observation period (Visit 3, from Day 1 after surgery until discharge, a final visit (at discharge) and a follow-up (day 6±1). Pain at rest will be assessed at screening and on visit 2 at baseline (0 h), 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and 48 h after anaesthetic IT injection and at discharge, using a 0-100 mm VAS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria Phase 1 and Phase 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
Drug: Paracetamol 3% · Drug: Hyperbaric Bupivacaine HCl 0.5%
90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
Drug: Paracetamol 3% · Drug: Hyperbaric Bupivacaine HCl 0.5%
120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
Drug: Paracetamol 3% · Drug: Hyperbaric Bupivacaine HCl 0.5%
Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
Drug: Placebo injection containing Saline solution 0.9% · Drug: Hyperbaric Bupivacaine HCl 0.5%
Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
NIMP, spinal anaesthetic before the surgical procedure
Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol
Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled
Time frame: In the first 24 hours, in the first 48 hours and at day 7±1
Phase 2: Pain Intensity
Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)
Time frame: baseline (0 h), 1, 6, 9, 12, 15, 24, and 48 h after anaesthetic IT injection and at discharge
Phase 2: Morphine
Phase 2: Total morphine use
Time frame: At 24 and 48 h after anaesthetic IT injection and entire study period, up to 7 days
Phase 2: Time to First Morphine Use
Phase 2: Time to first morphine use (minutes)
Time frame: Postoperative, up to 48 hours after end of surgery
Phase 2: Number of Participants With Need for Supplemental Analgesia
Phase 2: Need for supplementary analgesia, other than the planned morphine PCA
Time frame: Postoperative, up to 48 hours after end of surgery
Phase 2: Morphine-related Adverse Events
Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol
Time frame: up to 24 hours after surgery, up to 48 hours
Phase 2: Time to Readiness for Surgery
Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.
Time frame: Intraoperative
Phase 2:Maximum Level of Sensory Block
Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)
Time frame: Intraoperative
Phase 2: Time to Sensory Block
Time to maximum level of sensory block
Time frame: Intraoperative
Phase 2: Time to Regression of Spinal Block
Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale: I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet
Time frame: from readiness for surgery,then every 10 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 30 min until regression of spinal block
Phase 2: Vital Signs
Systolic and Diastolic Blood Pressure (mmHg)
Time frame: at screening, at baseline (before the spinal injection) and at end of the study (Day 6).
Phase2: Concomitant Medications
record the concomitant medications intaked during the study
Time frame: at screening, at baseline until the end of the study (Day 6)
Phase 2: SpO2
Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.
Time frame: at screening, at baseline (before the spinal injection) and at the end of the study (day 6)
Phase 2: ECG
Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.
Time frame: screening, baseline and end of study (Day 6±1)
| Milestone | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 0 |
| Completed | 3 | 3 | 3 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Started | 15 | 15 | 15 | 15 |
| Completed | 15 | 15 | 15 | 15 |
| Not completed | 0 | 0 | 0 | 0 |
Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled
| participants | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) |
|---|---|---|---|
| Adverse event related | 0 | 0 | 0 |
| Adverse event not related | 1 | 1 | 6 |
| Serious adverse event | 0 | 0 | 0 |
Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)
| units on a scale | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| baseline | 11.9 ± 15.5 | 17.3 ± 15.6 | 24.5 ± 19.5 | 10.7 ± 13.4 |
| 1 hour after anaesthetic | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| 6 hours after anaesthetic | 21.5 ± 22.2 | 32.2 ± 25 | 20.3 ± 25.3 | 42.3 ± 31.5 |
| 9 hours after anaesthetic | 21.6 ± 18 | 13.6 ± 11.6 | 17.3 ± 24 | 26.3 ± 22.3 |
| 12 hours after anaesthetic | 13.1 ± 16.5 | 10.1 ± 8.6 | 11.2 ± 17.5 | 17.9 ± 16.7 |
| 15 hours after anaesthetic | 15.4 ± 16.7 | 10.2 ± 10.2 | 10.6 ± 13.8 | 20.5 ± 21.5 |
| 24 hours after anaesthetic | 11.4 ± 10.7 | 9.5 ± 8.9 | 13.6 ± 14.9 | 16 ± 18.3 |
| 48 hours after anaesthetic | 6.1 ± 8.6 | 3.2 ± 6.6 | 7.7 ± 12.9 | 8.7 ± 11.6 |
| Discharge | 2.5 ± 3.7 | 4.1 ± 4.8 | 4.8 ± 6.8 | 8.0 ± 9.6 |
Phase 2: Total morphine use
| mg | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| first 24 hours | 14.1 ± 10.4 | 12.6 ± 4.5 | 22.8 ± 14.7 | 14.3 ± 7.4 |
| first 48 hours | 24.5 ± 19.7 | 15.8 ± 5.1 | 33.5 ± 21.5 | 21 ± 12.8 |
| entire study period | 24.8 ± 19.7 | 15.8 ± 5.1 | 33.8 ± 21.4 | 21.1 ± 13 |
Phase 2: Time to first morphine use (minutes)
| minutes | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Phase 2: Time to First Morphine Use | 351 (275 to 503) | 236 (181 to 322) | 318 (184 to 415) | 279 (169 to 313) |
Phase 2: Need for supplementary analgesia, other than the planned morphine PCA
| Participants | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Phase 2: Number of Participants With Need for Supplemental Analgesia | 9 | 11 | 11 | 10 |
Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol
| Participants | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Phase 2: Morphine-related Adverse Events | 1 | 6 | 1 | 6 |
Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.
| minutes | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Phase 2: Time to Readiness for Surgery | 9 (5 to 16) | 10 (4 to 10) | 10 (5 to 11) | 8 (5 to 12) |
Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)
| participants | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| T1 | 0 | 0 | 0 | 0 |
| T2 | 0 | 0 | 0 | 0 |
| T3 | 0 | 0 | 0 | 0 |
| T4 | 0 | 2 | 0 | 1 |
| T5 | 2 | 1 | 0 | 0 |
| T6 | 4 | 4 | 3 | 3 |
| T7 | 1 | 2 | 1 | 6 |
| T8 | 7 | 7 | 10 | 28 |
| T9 | 0 | 2 | 0 | 2 |
| T10 | 2 | 0 | 1 | 0 |
| T11 | 1 | 0 | 0 | 0 |
Time to maximum level of sensory block
| minutes | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Phase 2: Time to Sensory Block | 18 (13 to 20) | 15 (9 to 20) | 15 (13 to 20) | 17 (10 to 23) |
Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale: I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet
| minutes | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| Phase 2: Time to Regression of Spinal Block | 285 (260 to 345) | 246 (228 to 280) | 265 (245 to 303) | 280 (232 to 302) |
Systolic and Diastolic Blood Pressure (mmHg)
| mmHg | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| systolic Blood Pressure at screening | 137 ± 20.4 | 144.6 ± 20.5 | 148.5 ± 14.7 | 147.7 ± 15.7 |
| systolic Blood Pressure at baseline | 145.5 ± 13.6 | 146.3 ± 19.2 | 138.7 ± 10.5 | 144.8 ± 12.3 |
| systolic Blood Pressure at end of the study (day6) | 130 ± 14.6 | 130.3 ± 11.3 | 133.5 ± 10.2 | 138.1 ± 14.5 |
| Diastolic Blood Pressure at screening | 87.1 ± 11.3 | 85.7 ± 7 | 90.9 ± 8.2 | 87 ± 5.1 |
| Diastolic Blood Pressure at baseline | 83 ± 8.8 | 78.9 ± 10.3 | 77.8 ± 10 | 85.9 ± 5.8 |
| Diastolic Blood Pressure at end of the study (day6) | 79.5 ± 10.8 | 78.2 ± 7.5 | 79 ± 6.8 | 83.1 ± 9.3 |
record the concomitant medications intaked during the study
| participants | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| heparin group | 15 | 15 | 15 | 15 |
| Second-generation cephalosporins | 15 | 15 | 15 | 15 |
| Solutions affecting the electrolyte balance | 15 | 15 | 15 | 15 |
| Direct factor Xa inhibi | 15 | 15 | 14 | 15 |
| Amino acids | 14 | 13 | 12 | 15 |
| propofol | 11 | 13 | 13 | 14 |
| Adrenergic and dopaminergic agents | 10 | 11 | 12 | 12 |
| Propionic acid derivatives | 7 | 8 | 10 | 6 |
| Pyrazolones | 4 | 7 | 11 | 9 |
| Acetic acid derivatives and related substances | 6 | 7 | 8 | 8 |
| Osmotically acting laxatives | 1 | 3 | 6 | 3 |
| Proton pump inhibitors | 2 | 4 | 4 | 3 |
| Serotonin (5HT3) antagonists | 1 | 6 | 2 | 4 |
| Benzodiazepine derivatives | 2 | 0 | 4 | 2 |
| ANTIEMETICS AND ANTINAUSEANTS | 1 | 2 | 1 | 3 |
| Other opioids | 1 | 1 | 1 | 2 |
| Platelet aggregation inhibitors excl. heparin | 1 | 1 | 0 | 1 |
| Angiotensin II antagonists, | 1 | 1 | 0 | 0 |
| Natural opium alkaloids | 0 | 0 | 1 | 1 |
Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.
| Oxygen Saturation percentage | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| screening | 97.93 ± 0.59 | 98 ± 0.53 | 98.27 ± 0.70 | 97.80 ± 0.77 |
| baseline | 97.27 ± 1.03 | 97.07 ± 1.03 | 97.33 ± 1.18 | 96.87 ± 1.36 |
| end of the study (day 6) | 97.73 ± 1.03 | 97.53 ± 0.83 | 97.8 ± 0.77 | 97.6 ± 0.74 |
Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.
| Participants | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| screening — normal | 10 | 9 | 11 | 11 |
| screening — Abnormal, Not Clinically Significant | 5 | 6 | 4 | 4 |
| screening — Abnormal, Clinically Significant | 0 | 0 | 0 | 0 |
| baseline — normal | 13 | 11 | 11 | 12 |
| baseline — Abnormal, Not Clinically Significant | 2 | 4 | 4 | 3 |
| baseline — Abnormal, Clinically Significant | 0 | 0 | 0 | 0 |
| end of study — normal | 12 | 13 | 11 | 12 |
| end of study — Abnormal, Not Clinically Significant | 3 | 2 | 4 | 3 |
| end of study — Abnormal, Clinically Significant | 0 | 0 | 0 | 0 |
Collected over Clinical study duration (7 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 60 mg Paracetamol 3% (2 mL) | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| 90 mg Paracetamol 3% (3 mL) | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| 120 mg Paracetamol 3% (4mL) | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| Phase II Only: Saline Solution 0.9% | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Event | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% |
|---|---|---|---|---|
| hypotensionVascular disorders | 6/18 | 3/18 | 8/18 | 5/15 |
| procedural nauseaInjury, poisoning and procedural complications | 1/18 | 7/18 | 3/18 | 5/15 |
| postprocedural constipationInjury, poisoning and procedural complications | 0/18 | 3/18 | 6/18 | 4/15 |
| urinary retention postoperativeInjury, poisoning and procedural complications | 1/18 | 0/18 | 4/18 | 1/15 |
| headacheNervous system disorders | 1/18 | 1/18 | 3/18 | 0/15 |
| procedural vomitingInjury, poisoning and procedural complications | 0/18 | 2/18 | 1/18 | 1/15 |
| bradycardiaCardiac disorders | 0/18 | 1/18 | 1/18 | 1/15 |
| atrial fibrillationCardiac disorders | 0/18 | 0/18 | 0/18 | 1/15 |
| antiementic supportive careSurgical and medical procedures | 0/18 | 0/18 | 0/18 | 1/15 |
| joint dislocationInjury, poisoning and procedural complications | 0/18 | 1/18 | 0/18 | 0/15 |
| Age, Continuous(years) | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% | Total |
|---|---|---|---|---|---|
| Mean | 66.9 ± 6.7 | 65.1 ± 7.9 | 62.3 ± 9.3 | 65.1 ± 7.7 | 64.8 ± 7.9 |
| Sex: Female, Male(Participants) | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% | Total |
|---|---|---|---|---|---|
| Female | 8 | 13 | 4 | 6 | 31 |
| Male | 10 | 5 | 14 | 9 | 38 |
| Race (NIH/OMB)(Participants) | 60 mg Paracetamol 3% (2 mL) | 90 mg Paracetamol 3% (3 mL) | 120 mg Paracetamol 3% (4mL) | Phase II Only: Saline Solution 0.9% | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 18 | 18 | 18 | 15 | 69 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Nov 2016, a primary completion of Feb 2019 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2021, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
Sintetica SA